Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.
about
Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in ParkinsonĀ“s disease patients with motor complicationsMonoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's diseaseTime to change the blind men and the elephant approach to Parkinson disease?Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonistsTolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trialsDopamine agonists in Parkinson's diseaseMovement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendationsImpact of newer pharmacological treatments on quality of life in patients with Parkinson's diseasePramipexole-induced somnolence and episodes of daytime sleep.Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease.Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson'Nonergot dopamine-receptor agonists for treating Parkinson's disease - a network meta-analysis.Ropinirole and pramipexole, the new agonists.Parkinson's disease management: towards a new paradigm.The efficacy and safety of adjunct bromocriptine therapy for levodopa-induced motor complications: a systematic review.Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease.Pramipexole for levodopa-induced complications in Parkinson's disease.Apomorphine: an underutilized therapy for Parkinson's disease.Pharmacological treatment of Parkinson's disease.Pramipexole in the treatment of advanced Parkinson's disease.Current concepts in the diagnosis and management of Parkinson's diseaseDrug selection and timing of initiation of treatment in early Parkinson's disease.Role of pramipexole in the management of Parkinson's disease.Parkinson's disease: medical treatment of moderate to advanced disease.Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson's disease: implications for patients.Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre studyA short scale for the assessment of motor impairments and disabilities in Parkinson's disease: the SPES/SCOPAHealth-related quality of life as an outcome variable in Parkinson's disease.Dyskinesias and treatment with pramipexole in patients with Parkinson's disease.The Missing Medians: Exclusion of Ordinal Data from Meta-Analyses.Clinical aspects and management of levodopa-induced dyskinesia.Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.Pramipexole in the treatment of Parkinson's disease: new developments.Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?Update on the use of pramipexole in the treatment of Parkinson's disease.Use of the dopamine receptor agonist Mirapex in the treatment of Parkinson's disease.Current status of symptomatic medical therapy in Parkinson's diseaseTreatment of levodopa-induced motor complications.Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis.
P2860
Q24234273-98CD1A2A-C2F8-45EB-BA7F-69650FE5DDD5Q24240186-82155759-1A1F-4F68-94F6-4090F1189EACQ27693350-7D38B08F-98EF-44ED-8039-4FE4D05BD537Q28201003-21E24B99-D01F-485A-803F-BA8275E2E1A3Q28270780-72F9E8FE-7A93-4065-AF17-26D4626D7A72Q28276692-C6449D70-2D5A-4EE8-AB94-EE156D91973CQ28282629-AE86C167-F36A-4107-8734-06D18BCAF229Q28283547-987BE6AC-36AD-4F1D-9D28-F4C59293AC62Q31422765-EFCD2EC2-5C3A-4822-8973-500BE0C79586Q33260250-40A8DB70-0A6C-4439-B2C3-390A87E02761Q33260251-228A5A29-6E58-4525-A418-3AE25FE47114Q33604937-69903A7B-1C23-4D93-A28C-AE92EC6A94AEQ33714127-9FA15BC6-22FC-4ADF-B728-F6A6DD330499Q33714139-2E653561-AD67-475E-8526-768DB978F615Q33816867-0620B548-5827-439D-8720-CBD65FE02DF0Q33978622-E007389F-D254-4D41-92FC-D76DC2C491F1Q33978631-DBA67BF5-5A1A-4FC4-98FE-96F86AAB05B2Q34048141-D171F528-1540-4172-AD2B-1F4A56E15332Q34048261-83C57502-3BAC-4328-A2CB-05913E416136Q34071723-7E03EA0A-AE92-49BD-BAAE-D7C14FDEE4ADQ34458284-9CF9882D-42A2-4CB1-B73E-89661F893B86Q34602815-6365FC31-162F-4C24-AB68-F67697DFBC83Q34623437-1A533584-143F-48B0-99DF-95BCB8C3532CQ34666449-E68714CF-0E70-432D-B1B9-C416EEFD9755Q35006707-4816E8FF-DFBC-447C-8DA8-09360E33661BQ35450779-7CADEB85-0938-410E-8A4D-920C39A6567FQ35468072-5282741F-2831-4A5B-B4C5-11275A1351CAQ35479549-C76E9338-7692-4FD5-AD9F-0B86348A5EE5Q35825918-6F9290E6-B3DB-4590-AB2D-0A46DA815CB7Q35837892-2F11D653-4BD9-4984-89B7-A49ED28AC7F9Q35876455-32B3BEAE-9B17-478C-A99B-00841E03B639Q36022700-50C66B7D-83C9-4C6E-9103-0AC64678F105Q36094535-C68DCC97-0A91-4BE3-969C-6FF667A2C9F2Q36257184-5D05C1F6-C25C-431B-992C-24D2854C2CA5Q36587747-C8864380-006F-4CC9-82B5-441F862C75B2Q36842189-79ACBF22-0132-4974-8C33-29661DBFE42FQ36893605-97ACB4B9-EFAA-4C1B-8B13-FEB3529EC8ADQ37131229-3988B6DA-4E84-4A26-83A2-03059F5449A1Q37264482-D830BC4E-D60D-4858-A0F2-C402AFD03B8EQ37736512-781DB79C-FB77-42D8-8EEE-16B95CCEF8C5
P2860
Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.
description
1997 nĆ® lÅ«n-bĆ»n
@nan
1997幓ć®č«ę
@ja
1997幓å¦ęÆęē«
@wuu
1997幓å¦ęÆęē«
@zh-cn
1997幓å¦ęÆęē«
@zh-hans
1997幓å¦ęÆęē«
@zh-my
1997幓å¦ęÆęē«
@zh-sg
1997幓åøč”ęē«
@yue
1997幓åøč”ęē«
@zh
1997幓åøč”ęē«
@zh-hant
name
Double-blind comparison of pra ...... ole-Bromocriptine Study Group.
@en
Double-blind comparison of pra ...... ole-Bromocriptine Study Group.
@nl
type
label
Double-blind comparison of pra ...... ole-Bromocriptine Study Group.
@en
Double-blind comparison of pra ...... ole-Bromocriptine Study Group.
@nl
prefLabel
Double-blind comparison of pra ...... ole-Bromocriptine Study Group.
@en
Double-blind comparison of pra ...... ole-Bromocriptine Study Group.
@nl
P356
P1433
P1476
Double-blind comparison of pra ...... ole-Bromocriptine Study Group.
@en
P2093
P304
P356
10.1212/WNL.49.4.1060
P407
P577
1997-10-01T00:00:00Z